News & Events Year None201820172016201520142013201220112009 06/12/18 REGENXBIO Receives FDA Fast Track Designation for RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I 06/11/18 REGENXBIO Receives $100 Million Accelerated License Payment Due to Acquisition of AveXis by Novartis 05/29/18 Alexandra Glucksmann Joins REGENXBIO Board of Directors 05/15/18 REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation 05/09/18 REGENXBIO to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference 05/08/18 REGENXBIO Reports First Quarter 2018 Financial Results and Recent Operational Highlights 05/02/18 REGENXBIO Receives FDA Fast Track Designation for RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
